日前，日本札幌醫(yī)科大學(xué)教授加藤淳二率領(lǐng)的研究小組在新一期美國(guó)《公共科學(xué)圖書館—綜合》（PLoS ONE）上報(bào)告說,，他們開發(fā)出一種治療胰腺癌的新療法，即利用癌細(xì)胞能吸收海藻糖的性質(zhì),，在化療過程中使癌細(xì)胞直接“吃藥”,，從而能夠減少藥量，并減小化療藥物對(duì)健康細(xì)胞的影響,。
研究小組發(fā)現(xiàn),，胰腺癌細(xì)胞具有活躍吸收海藻糖的性質(zhì)，于是將海藻糖與內(nèi)部包有化療藥物的稱為脂質(zhì)體的薄膜結(jié)合在一起,，然后注射到小鼠體內(nèi),，結(jié)果成功地將藥物輸送到了癌細(xì)胞處。
研究小組成員,、札幌醫(yī)科大學(xué)講師瀧本理修說：“這是一種讓癌細(xì)胞自己積極吸收化療藥物的新療法,。”研究小組今后準(zhǔn)備開展臨床試驗(yàn)。
研究小組認(rèn)為,，基于癌細(xì)胞吸收海藻糖的性質(zhì),，這種方法還能夠用于治療胃癌、大腸癌和膽管癌,。（生物谷Bioon.com）
doi:10.1371/journal.pone.0039545
PMC:
PMID:
Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach
Makoto Yoshida1,2, Rishu Takimoto1,2, Kazuyuki Murase1, Yasushi Sato1, Masahiro Hirakawa1,2, Fumito Tamura1,2, Tsutomu Sato1,3, Satoshi Iyama1, Takahiro Osuga1, Koji Miyanishi1, Kohichi Takada1, Tsuyoshi Hayashi1, Masayoshi Kobune3, Junji Kato
Owing to its aggressiveness and the lack of effective therapies, pancreatic ductal adenocarcinoma has a dismal prognosis. New strategies to improve treatment and survival are therefore urgently required. Numerous fucosylated antigens in sera serve as tumor markers for cancer detection and evaluation of treatment efficacy. Increased expression of fucosyltransferases has also been reported for pancreatic cancer. These enzymes accelerate malignant transformation through fucosylation of sialylated precursors, suggesting a crucial requirement for fucose by pancreatic cancer cells. With this in mind, we developed fucose-bound nanoparticles as vehicles for delivery of anticancer drugs specifically to cancer cells. L-fucose-bound liposomes containing Cy5.5 or Cisplatin were effectively delivered into CA19-9 expressing pancreatic cancer cells. Excess L-fucose decreased the efficiency of Cy5.5 introduction by L-fucose-bound liposomes, suggesting L-fucose-receptor-mediated delivery. Intravenously injected L-fucose-bound liposomes carrying Cisplatin were successfully delivered to pancreatic cancer cells, mediating efficient tumor growth inhibition as well as prolonging survival in mouse xenograft models. This modality represents a new strategy for pancreatic cancer cell-targeting therapy.
